Design Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Design Therapeutics, Inc. (DSGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 3.94 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-03
- Design Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 192.50K shares, a 68.65% decline year-over-year.
- Design Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 3.75M shares, a 18.79% increase year-over-year.
- Design Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Design Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 165.83K shares, a 2111.11% increase year-over-year.
- Design Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 3.93M shares, a 39.56% increase from fiscal 2024.
- Design Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.82M shares, a 46.81% decline from fiscal 2023.
- Design Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 5.30M shares, a 69.18% increase from fiscal 2022.
- Design Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 3.13M shares, a 117.60% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 192.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | 3.94M shares 10-Q · filed 2026-08-03 | 3.94M shares derived: sum of 3 quarters · filed 2026-08-03 | 4.10M shares derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | 3.75M shares 10-Q · filed 2026-04-28 | 3.75M shares derived: sum of 2 quarters · filed 2026-04-28 | 3.91M shares derived: sum of 3 quarters · filed 2026-04-28 | 4.53M shares derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 165.83K shares derived: sum of 2 quarters · filed 2026-03-09 | 779.83K shares derived: sum of 3 quarters · filed 2026-03-09 | 3.93M shares 10-K · filed 2026-03-09 |
| 2025-09-30 | 165.83K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 779.83K shares derived: sum of 2 quarters · filed 2025-11-05 | 3.93M shares 10-Q · filed 2025-11-05 | 4.13M shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 614.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 3.77M shares 10-Q · filed 2025-08-07 | 3.97M shares derived: sum of 3 quarters · filed 2025-08-07 | 3.97M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 3.15M shares 10-Q · filed 2025-05-07 | 3.35M shares derived: sum of 2 quarters · filed 2025-05-07 | 3.36M shares derived: sum of 3 quarters · filed 2025-05-07 | 3.47M shares derived: sum of 4 quarters · filed 2025-05-07 |
| 2024-12-31 | 199.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | 207.00K shares derived: sum of 2 quarters · filed 2025-03-10 | 321.00K shares derived: sum of 3 quarters · filed 2025-03-10 | 2.82M shares 10-K · filed 2025-03-10 |
| 2024-09-30 | 7.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 121.50K shares derived: sum of 2 quarters · filed 2024-11-07 | 2.62M shares 10-Q · filed 2024-11-07 | 3.01M shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 114.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | 2.61M shares 10-Q · filed 2024-08-05 | 3.00M shares derived: sum of 3 quarters · filed 2024-08-05 | 5.15M shares derived: sum of 4 quarters · filed 2024-08-05 |
| 2024-03-31 | 2.50M shares 10-Q · filed 2024-05-08 | 2.89M shares derived: sum of 2 quarters · filed 2024-05-08 | 5.03M shares derived: sum of 3 quarters · filed 2024-05-08 | 5.22M shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 391.69K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | 2.54M shares derived: sum of 2 quarters · filed 2024-03-19 | 2.72M shares derived: sum of 3 quarters · filed 2024-03-19 | 5.30M shares 10-K · filed 2024-03-19 |
| 2023-09-30 | 2.14M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 2.33M shares derived: sum of 2 quarters · filed 2023-11-13 | 4.91M shares 10-Q · filed 2023-11-13 | 5.05M shares derived: sum of 4 quarters · filed 2024-03-19 |
| 2023-06-30 | 183.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 2.76M shares 10-Q · filed 2023-08-14 | 2.90M shares derived: sum of 3 quarters · filed 2024-03-19 | 3.14M shares derived: sum of 4 quarters · filed 2024-03-19 |
| 2023-03-31 | 2.58M shares 10-Q · filed 2023-05-09 | 2.72M shares derived: sum of 2 quarters · filed 2024-03-19 | 2.96M shares derived: sum of 3 quarters · filed 2024-03-19 | 3.22M shares derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-12-31 | 140.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | 377.50K shares derived: sum of 2 quarters · filed 2024-03-19 | 634.50K shares derived: sum of 3 quarters · filed 2024-03-19 | 3.13M shares 10-K · filed 2024-03-19 |
| 2022-09-30 | 237.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 494.50K shares derived: sum of 2 quarters · filed 2022-11-03 | 2.99M shares 10-Q · filed 2022-11-03 | |
| 2022-06-30 | 257.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 2.75M shares 10-Q · filed 2022-08-08 | ||
| 2022-03-31 | 2.50M shares 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | 1.44M shares 10-K · filed 2023-03-14 | |||
| 2020-12-31 | 1.72M shares 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |